|
Implementation strategies for monitoring adherence in real time (iSMART): A pilot randomized trial. |
|
|
Honoraria - MJH Healthcare Holdings, LLC |
Consulting or Advisory Role - Merck |
Research Funding - AstraZeneca; Pfizer (Inst) |
Travel, Accommodations, Expenses - MJH Healthcare Holdings, LLC |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Memora Health |
Stock and Other Ownership Interests - Memora Health |
|
|
No Relationships to Disclose |
|
|
Employment - Memora Health |
Leadership - Memora Health |
Travel, Accommodations, Expenses - Memora Health |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Reimagine Care |
Honoraria - National Comprehensive Cancer Network |
Consulting or Advisory Role - Reimagine Care; UnitedHealthcare |
Research Funding - Loxo@Lilly (Inst) |
|
|
Research Funding - Pfizer |
Expert Testimony - GlaxoSmithKline |
|
|
Consulting or Advisory Role - Sage Therapeutics |
|
|
Consulting or Advisory Role - Genentech |
Research Funding - Celgene (Inst); Independence Blue Cross (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Sanofi/Regeneron; Shionogi; Turning Point Therapeutics |
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I) |
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst) |
|
|
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation |
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda |
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst) |
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Synta |
|
|
Stock and Other Ownership Interests - Bluebird Bio (I); Gilead Sciences (I); Johnson & Johnson (I); Merck (I); Novartis (I); Pfizer (I); Pfizer (I); Portola Pharmaceuticals (I) |
Consulting or Advisory Role - AstraZeneca/Merck; Boehringer Ingelheim (I); Genentech; Health Advances; Novartis (I); Novocure (I) |
Research Funding - AstraZeneca (I); Lilly (I); Pfizer; Trizell (I) |